Medline Issues Correction for Convenience Kits Containing Huons Bupivacaine Hydrochloride in Dextrose Injection

A supplier-level manufacturing deficiency at Huons Co., Ltd. has propagated downstream into a Class I correction at Medline Industries, exposing a supply-chain vulnerability that QA directors and incoming-material teams at surgical facilities should treat as an active qualification gap. The FDA has classified this as its most serious correction category, citing risks that include infection, inflammatory response, reduced anesthetic effectiveness, and, when product is used in the neuraxial space, cerebral fluid contamination and meningitis with potential progression to encephalitis.

The correction covers Medline convenience kits containing Bupivacaine Hydrochloride in Dextrose Injection, USP supplied by Huons Co., Ltd. Huons initiated its own recall following an FDA inspection of its manufacturing facility that identified quality issues; Medline's correction is a downstream consequence of that finding. As of April 10, 2026, Medline has reported no confirmed serious injuries or deaths linked to the affected lots.

Medline's customer letter, issued April 10, directs facilities to immediately quarantine affected kits, complete a recall response form, and await over-labels that instruct staff to remove and discard the Bupivacaine component before using remaining kit contents. All other components within the kits are cleared for continued use. Facilities that have redistributed or transferred affected product are required to notify downstream recipients.

For QA leads, the structural issue here runs deeper than a single lot disposition. Convenience kits that bundle pharmaceutical injectables with surgical instruments and dressings create a compounded qualification obligation: the injectable component carries its own 21 CFR Part 211 manufacturing requirements, while the kit itself is regulated as a medical device. When a pharmaceutical supplier triggers a recall, the device distributor inherits the correction burden, a dynamic that supplier qualification programs and incoming material testing protocols must explicitly account for.

Facilities managing surgical kit inventories should cross-reference affected lot numbers against the FDA Enforcement Report and the Huons Co., Ltd. recall entry in the Medical Device Recall Database. Questions can be directed to Medline at 1-866-359-1704 or recalls@medline.com.

The measurable checkpoint for affected sites is receipt and application of Medline's over-labels across all quarantined inventory before any kit components re-enter the sterile field.

Source: FDA MedWatch Safety Alerts RSS Feed via FDA.gov, June 12, 2026.